Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ripasudil

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 156,772Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aerie Announces Positive Phase 3 Topline Results for Netarsudil in Japan
    Aerie Announces Positive Phase 3 Topline Results for Netarsudil in Japan

    12 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211012005106/en

    BUSINESSWIRE
    12 Oct 2021
    Share Share
    Aerie Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil
    Aerie Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil

    17 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210617005036/en

    BUSINESSWIRE
    17 Jun 2021
    Share Share
    Rho kinase inhibitor,
    Rho kinase inhibitor, "Ripasudil Hydrochloride Hydrate" INDapp for Ph2 clinical

    03 Sep 2019

    // PR NEWSWIR

    https://www.prnewswire.com/news-releases/rho-kinase-inhibitor-ripasudil-hydrochloride-hydrate-ind-application-for-phase-2-clinical-study-in-the-united-states-indication-for-corneal-endothelial-diseases-developmental-code-k-321-300909856.html

    PR NEWSWIR
    03 Sep 2019
    Share Share